NasdaqGM - Nasdaq Real Time Price USD

Travere Therapeutics, Inc. (TVTX)

20.73

-0.21

(-1.00%)

As of 10:02:58 AM EDT. Market Open.

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

– Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4’24 – – Late-stage pipeline continues to advance with completion of end-of-Phase 2 meeting with Food and Drug Administration for VP-315, Verrica’s candidate for basal cell carcinoma, and continued advancement towards initiation of global Phase 3 program in common warts (VP-102/YCANTH)

GlobeNewswire 17 hours ago

VRCA

TVTX
-1.00%
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 12, 2025--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 35,900 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as induce

Business Wire yesterday

TVTX
-1.00%
Travere Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO, May 07, 2025--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:

Business Wire 6 days ago

TVTX
-1.00%
Analysts Have Made A Financial Statement On Travere Therapeutics, Inc.'s (NASDAQ:TVTX) First-Quarter Report

As you might know, Travere Therapeutics, Inc. ( NASDAQ:TVTX ) just kicked off its latest quarterly results with some...

Simply Wall St. 10 days ago

TVTX
-1.00%
Travere Therapeutics Reports First Quarter 2025 Financial Results

SAN DIEGO, May 01, 2025--Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update.

Business Wire 12 days ago

TVTX
-1.00%
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

SAN DIEGO & ST. GALLEN, Switzerland, April 29, 2025--Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing authorization (MA) for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). Standard MA is granted for all member states of the Europe

Business Wire 15 days ago

TVTX
-1.00%
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing authorization (MA) for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). Standard MA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and No

PR Newswire 15 days ago

TVTX
-1.00%

CMXHF

CSLLY
Travere Therapeutics to Report First Quarter 2025 Financial Results

SAN DIEGO, April 24, 2025--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Business Wire 19 days ago

TVTX
-1.00%
Exploring 3 High Growth Tech Stocks In The US Market

The United States stock market has recently experienced a surge, with major indices like the Dow Jones and Nasdaq Composite showing significant gains amid optimism over reduced China tariffs and easing concerns about Federal Reserve independence. In this environment of heightened risk appetite and tech sector rallies, identifying high-growth tech stocks involves looking for companies that not only show strong innovation potential but also demonstrate resilience in navigating trade tensions...

Simply Wall St. 20 days ago

TVTX
-1.00%

GERN

GERNW
Travere Therapeutics price target lowered to $30 from $32 at Scotiabank

Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an Outperform rating on the shares. The company recently presented updated data for its Filspari in IgA nephropathy and focal segmental glomerulosclerosis, reiterating the drug’s “robust clinical profile,” the analyst tells investors. While Vanrafia may out pressure on new patient starts, the firm believes Filspari’s launch should continue upward due to the drug’s differentia

TipRanks last month

TVTX
-1.00%
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025

SAN DIEGO, March 31, 2025--Travere's late-breaking oral presentation at NKF details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS

Business Wire last month

TVTX
-1.00%
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Additionally, the FDA notified the Company that REMS monitoring for embryo-fetal toxicity is no longer necessary; the Company plans to submit an amendment to the REMS sNDA currently under review for modification of liver monitoring SAN DIEGO, March 17,

GlobeNewswire last month

TVTX
-1.00%
High Growth Tech Stocks In The US With Promising Potential

Over the last 7 days, the United States market has dropped 4.1%, yet it remains up by 6.6% over the past year with earnings expected to grow by 14% per annum in the coming years. In this context, identifying high growth tech stocks that align with these positive earnings projections can be crucial for investors looking to capitalize on technological advancements and market resilience.

Simply Wall St. last month

LFMD

LFMDP

AAOI
Travere Therapeutics price target raised to $30 from $24 at TD Cowen

TD Cowen raised the firm’s price target on Travere Therapeutics (TVTX) to $30 from $24 and keeps a Buy rating on the shares. The firm said Q4 Filspari results were in line with the preannouncement with impressive 40% quarter-over-quarter sales growth and a 37% quarter-over quarter increase in PSFs. Filspari growth in IgAN should continue in 2025 as there are multiple tailwinds and the FSGS sNDA submission should occur by the end of Q1 setting up a potential approval by year-end. Published first

TipRanks 2 months ago

TVTX
-1.00%
Travere Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Travere Therapeutics ( NASDAQ:TVTX ) Full Year 2024 Results Key Financial Results Revenue: US$233.2m (up 61% from FY...

Simply Wall St. 2 months ago

TVTX
-1.00%
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full year 2024 Net product sales totaled $74 million in 4Q 2024; $227 million for full year 2024 SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2024 financial results and provided a corporate update. “Our strong executio

GlobeNewswire 2 months ago

TVTX
-1.00%
Travere Therapeutics (TVTX): Among The Small–Cap Stocks Insiders Are Selling Recently

We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Travere Therapeutics, Inc. (NASDAQ:TVTX) stands against other small–cap stocks insiders are selling recently. Why are some investors focusing on stocks with smaller market capitalizations? Among some of the reasons are […]

Insider Monkey 2 months ago

TVTX
-1.00%
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere’s website at ir.travere.com

GlobeNewswire 2 months ago

TVTX
-1.00%
Travere Therapeutics price target raised to $32 from $27 at Scotiabank

Scotiabank analyst Greg Harrison raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $27 and keeps an Outperform rating on the shares. The company recently announced plans to file a supplemental new drug application for Filspari and, while approval is not guaranteed, the firm suspects an sNDA submission would not have been suggested if the FDA was not open to considering an approval. Published first on TheFly – the ultimate source for real-time, market-moving breaking finan

TipRanks 2 months ago

TVTX
-1.00%
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated for FSGS, a rare kidney disorder and leading cause of kidney failure sNDA submission to be based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS Company to host conference call and webcast today at 8:30 a.m. ET SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Travere Therapeu

GlobeNewswire 2 months ago

TVTX
-1.00%

Performance Overview

Return	TVTX	S&P 500 (^GSPC)
YTD	+19.00%	+0.11%
1-Year	+209.40%	+12.23%
3-Year	-6.54%	+46.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Travere Therapeutics, Inc. (TVTX)

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Participate at Upcoming Investor Conferences

Analysts Have Made A Financial Statement On Travere Therapeutics, Inc.'s (NASDAQ:TVTX) First-Quarter Report

Travere Therapeutics Reports First Quarter 2025 Financial Results

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

Travere Therapeutics to Report First Quarter 2025 Financial Results

Exploring 3 High Growth Tech Stocks In The US Market

Travere Therapeutics price target lowered to $30 from $32 at Scotiabank

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

High Growth Tech Stocks In The US With Promising Potential

Travere Therapeutics price target raised to $30 from $24 at TD Cowen

Travere Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Travere Therapeutics (TVTX): Among The Small–Cap Stocks Insiders Are Selling Recently

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Travere Therapeutics price target raised to $32 from $27 at Scotiabank

Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS

Performance Overview